Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technol

Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technology, Application, End User - Global Forecast 2024-2030

The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 22.81 billion in 2023 and expected to reach USD 25.12 billion in 2024, at a CAGR 10.91% to reach USD 47.11 billion by 2030.

Next-generation breast cancer diagnostic & screening technologies represent a paradigm shift in how breast cancer is detected and diagnosed, offering more precise, efficient, and less invasive methods compared to traditional modalities. These advanced technologies, including digital mammography, 3D mammography (tomosynthesis), automated breast ultrasound, and molecular breast imaging, leverage high-end imaging and genomic profiling to identify breast cancers at an early stage when they are most treatable. Major factors driving the adoption of these novel diagnostic tools include the prevalence of breast cancer globally, increased awareness and advocacy for early detection, advancements in imaging technology, and a push toward personalized medicine. Despite their significant importance, these next-generation technologies face utility challenges such as high costs, limited access in low-resource settings, and the potential for overdiagnosis leading to unnecessary treatments. Addressing these restraints requires concerted efforts to reduce costs through technological innovations and scale, improving healthcare infrastructure, and implementing more nuanced screening protocols to balance early detection with the risk of overdiagnosis. Integration of artificial intelligence to improve diagnostic accuracy, the development of portable screening devices to increase access, and the continuous evolution of genomic profiling to predict breast cancer risk and tailor screening strategies accordingly are expected to expand the next-generation breast cancer diagnostic & screening space in the coming years.

Please Note: PDF & Excel + Online Access - 1 Year